Charles Schwab Investment Management Inc Arcus Biosciences, Inc. Transaction History

Charles Schwab Investment Management Inc

  • $557 Billion
  • Q2 2025

A detailed history of Charles Schwab Investment Management Inc transactions in Arcus Biosciences, Inc. stock. As of the latest transaction made, Charles Schwab Investment Management Inc holds 776,742 shares of RCUS stock, worth $13.6 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares
776,742
Previous 714,002 8.79%
Holding current value
$13.6 Million
Previous $5.6 Million 12.81%
% of portfolio
0.0%
Previous 0.0%

Shares

30 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2025

Aug 12, 2025
BUY
$6.87 - $10.03 $431,023 - $629,282
62,740 Added 8.79%
776,742 $6.32 Million
Q1 2025

Sep 15, 2025
SELL
$7.85 - $15.24 $492,509 - $956,157
-62,740 Reduced 8.08%
714,002 $5.6 Million
Q1 2025

May 09, 2025
BUY
$7.85 - $15.24 $1.05 Million - $2.05 Million
134,379 Added 23.18%
714,002 $5.6 Million
Q4 2024

Feb 06, 2025
BUY
$14.28 - $18.44 $180,556 - $233,155
12,644 Added 2.23%
579,623 $8.63 Million
Q3 2024

Nov 12, 2024
BUY
$13.69 - $18.01 $815,047 - $1.07 Million
59,536 Added 11.73%
566,979 $8.67 Million
Q2 2024

Aug 12, 2024
BUY
$14.59 - $18.48 $206,696 - $261,806
14,167 Added 2.87%
507,443 $7.73 Million
Q1 2024

May 08, 2024
BUY
$14.83 - $20.18 $312,824 - $425,676
21,094 Added 4.47%
493,276 $9.31 Million
Q4 2023

Feb 06, 2024
BUY
$13.43 - $19.63 $152,309 - $222,623
11,341 Added 2.46%
472,182 $9.02 Million
Q3 2023

Nov 08, 2023
BUY
$17.62 - $23.54 $424,642 - $567,314
24,100 Added 5.52%
460,841 $8.27 Million
Q2 2023

Aug 09, 2023
BUY
$16.97 - $22.03 $255,398 - $331,551
15,050 Added 3.57%
436,741 $8.87 Million
Q1 2023

May 11, 2023
BUY
$15.96 - $23.15 $526,217 - $763,278
32,971 Added 8.48%
421,691 $7.69 Million
Q4 2022

Feb 13, 2023
BUY
$19.7 - $35.71 $189,632 - $343,744
9,626 Added 2.54%
388,720 $8.04 Million
Q3 2022

Nov 14, 2022
BUY
$23.23 - $30.07 $831,935 - $1.08 Million
35,813 Added 10.43%
379,094 $9.92 Million
Q2 2022

Aug 15, 2022
BUY
$17.23 - $37.73 $217,614 - $476,529
12,630 Added 3.82%
343,281 $8.7 Million
Q1 2022

May 13, 2022
BUY
$28.92 - $41.83 $245,848 - $355,596
8,501 Added 2.64%
330,651 $10.4 Million
Q4 2021

Feb 11, 2022
SELL
$31.38 - $48.47 $1.04 Million - $1.6 Million
-33,091 Reduced 9.32%
322,150 $13 Million
Q3 2021

Nov 16, 2021
BUY
$26.93 - $37.68 $287,666 - $402,497
10,682 Added 3.1%
355,241 $12.4 Million
Q2 2021

Aug 16, 2021
BUY
$22.75 - $35.77 $256,802 - $403,771
11,288 Added 3.39%
344,559 $9.46 Million
Q1 2021

May 17, 2021
BUY
$26.16 - $41.39 $1.21 Million - $1.91 Million
46,191 Added 16.09%
333,271 $9.36 Million
Q4 2020

Feb 16, 2021
BUY
$17.0 - $32.36 $69,819 - $132,902
4,107 Added 1.45%
287,080 $7.45 Million
Q3 2020

Nov 13, 2020
BUY
$17.14 - $25.47 $457,980 - $680,558
26,720 Added 10.43%
282,973 $4.85 Million
Q2 2020

Aug 14, 2020
BUY
$13.97 - $36.56 $838,367 - $2.19 Million
60,012 Added 30.58%
256,253 $6.34 Million
Q1 2020

May 15, 2020
BUY
$8.78 - $19.28 $39,316 - $86,335
4,478 Added 2.34%
196,241 $2.72 Million
Q4 2019

Feb 07, 2020
BUY
$7.33 - $10.79 $15,231 - $22,421
2,078 Added 1.1%
191,763 $1.94 Million
Q3 2019

Nov 08, 2019
BUY
$6.44 - $10.18 $596,073 - $942,240
92,558 Added 95.3%
189,685 $1.73 Million
Q2 2019

Aug 09, 2019
SELL
$7.29 - $13.38 $11,729 - $21,528
-1,609 Reduced 1.63%
97,127 $773,000
Q1 2019

May 14, 2019
BUY
$8.95 - $12.49 $43,828 - $61,163
4,897 Added 5.22%
98,736 $1.23 Million
Q4 2018

Feb 14, 2019
BUY
$9.74 - $14.5 $419,716 - $624,834
43,092 Added 84.92%
93,839 $1.01 Million
Q3 2018

Nov 13, 2018
BUY
$10.88 - $14.95 $116,481 - $160,054
10,706 Added 26.74%
50,747 $708,000
Q2 2018

Aug 08, 2018
BUY
$12.24 - $17.05 $490,101 - $682,699
40,041 New
40,041 $491,000

Others Institutions Holding RCUS

# of Institutions
212
Shares Held
67M
Call Options Held
3.18M
Put Options Held
167K
View Full List

About Arcus Biosciences, Inc.

RCUS Quotes by TradingView
  • Ticker RCUS
  • Exchange NYSE
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 72,160,000
  • Market Cap $1.26B
  • Description
  • Arcus Biosciences, Inc., a clinical-stage biopharmaceutical company, develops and commercializes cancer therapies in the United States. Its product pipeline includes, Etrumadenant, a dual A2a/A2b adenosine receptor antagonist, which is in a Phase 1b/2 clinical trial; and Zimberelimab, an anti-PD-1 antibody that is in Phase 1b clinical trial for ...
More about RCUS
Track This Portfolio

Track Charles Schwab Investment Management Inc Portfolio

Follow Charles Schwab Investment Management Inc and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Charles Schwab Investment Management Inc, based on Form 13F filings with the SEC.

News

Stay updated on Charles Schwab Investment Management Inc with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email